Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy

Canadian Journal of Ophthalmology

Volumn 40, Issue 5, 2005, Pages 598-604

  Munir, Wuqaas M ^a   Pulido, Jose S ^a,b   Sharma, Mithlesh C ^a   Buerk, Bruce M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Intravitreal steroids; Pars plana vitrectomy; Proliferative diabetic retinopathy; Proliferative vitreoretinopathy; Triamcinolone acetonide

Indexed keywords

SILICONE OIL; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CILIARY DISK; CLINICAL ARTICLE; COMPUTER; CRYSTAL; DATA BASE; DEMOGRAPHY; DIABETIC RETINOPATHY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; MEDICAL INFORMATION; OUTCOMES RESEARCH; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRESSURE MEASUREMENT; RETINA DETACHMENT; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VISION; VITRECTOMY; VITREORETINOPATHY;

EID: 27644557312     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/S0008-4182(05)80052-3     Document Type: Article

References (26)

1. Sharma T, Gopal L, Shanmugam MP, et al. Management of recurrent retinal detachment in silicone oil-filled eyes. Retina 2002;22:153-7.
2. Castellarin A, Grigorian R, Bhagat N, et al. Vitrectomy with silicone oil infusion in severe diabetic retinopathy. Br J Ophthalmol 2003;87:318-21.
3. Lewis H, Burke JM, Abrams GW, et al. Perisilicone proliferation after vitrectomy for proliferative vitreoretinopathy. Ophthalmology 1988;95:583-91.
4. Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001;108:1179-83.
5. McCuen BW II, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-8.
6. Schindler RH, Chandler DB, Thresher R, et al. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:4l5-7.
7. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979;77:171-80.
8. Tano Y, Sugita G, Abrams G, et al. Inhibition of intraocular proliferation with intravitreal corticosteroid. Am J Ophthalmol 1980;89:131-6.
9. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810-6.
10. Kraff MC, Martin RG, Neumann AC, Weinstein AJ. Efficacy of diclofenac sodium ophthalmic solution versus placebo in reducing inflammation following cataract extraction and posterior chamber lens implantation. J Cat Refract Surg 1994;20:138-44.
11. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
12. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26:277-81.
13. Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-50.
14. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000;84:1064-7.
15. Jonas JB, Hayler JK, Sofker A, et al. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001;131:468-71.
16. Jonas JB, Sofker A, Degenring R. Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2003;13:468-73.
17. Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001;29:2-6.
18. Jonas JB, Kreissig I, Degenering R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-7.
19. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999;27:431-2.
20. Jonas JB, Kreissig I, Degenring R. Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol 2003;121:729-30.
21. Abrams GW, Azen SP, McCuen BW, et al. Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up: Silicone Study Report 11. Arch Ophthalmol 1997;115:335-44.
22. Hida T, Chandler D, Arena JE, et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986;101:190-5.
23. Peyman GA, Cheema R, Conway MD, et al. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 2000;20:554-5.
24. Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exl Ophthalmol 2002;240:423-9.
25. Jonas JB. Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil. Br J Ophthalmol 2002;86:1450-1.
26. Kivilcim M, Peyman GA, El-Dessouky E, et al. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 2000;31:474-8.